{"id":"W4399285742","doi":"10.1038/s41591-024-02986-9","title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"Loxo Oncology; Pharmacyclics; Chugai Pharmaceutical; Genentech; EMD Serono; MorphoSys; SymBio Pharmaceuticals Limited; BeiGene; Mitsubishi Tanabe Pharma Corporation; Seagen; Celgene; Alimera Sciences; Eisai; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; TG Therapeutics; bluebird bio; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Calithera Biosciences; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Alexion Pharmaceuticals; Karyopharm Therapeutics; Sanofi; Amgen; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Follicular lymphoma; Refractory (planetary science); Internal medicine; Follicular phase; Lymphoma; Oncology; Confidence interval; Rituximab; CD20; Clinical endpoint; Gastroenterology; Clinical trial; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001703396,0.0003035827,0.0005831437,0.0004699333,0.00007930528,0.0000315349,0.0003126205,0.0003181713,0.003573931],"category_scores_gemma":[0.0002286516,0.0001650965,0.0001613698,0.001490641,0.0002306133,0.00006634357,0.00003993403,0.001560323,0.00005847815],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000256508,"about_ca_system_score_gemma":0.0002080551,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001983098,"about_ca_topic_score_gemma":0.0001805415,"domain_scores_codex":[0.9970109,0.0002045006,0.0004371852,0.0005730208,0.001271895,0.0005024465],"domain_scores_gemma":[0.9985991,0.0003447933,0.00002851935,0.0007194084,0.00009906565,0.0002091235],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004061016,0.005066373,0.007638753,0.0008405168,0.001312836,0.01904875,0.01768879,0.000005482098,0.3796277,0.0005689008,0.04591293,0.5182279],"study_design_scores_gemma":[0.05575145,0.006872099,0.04166045,0.001494303,0.000933441,0.0009117946,0.00558337,0.002157196,0.01280557,0.0003228695,0.8709774,0.0005300335],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9112136,0.0499756,0.00004190916,0.02808327,0.001033104,0.00216494,0.000009351789,0.000154433,0.007323829],"genre_scores_gemma":[0.9827103,0.0007607638,0.00002341337,0.001790988,0.00167402,0.0001098566,0.00004574784,0.00007121377,0.01281367],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8250645,"threshold_uncertainty_score":0.9973369,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0222716939987892,"score_gpt":0.3854360734110371,"score_spread":0.3631643794122479,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}